Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania;
Rom J Morphol Embryol. 2022 Jul-Sep;63(3):521-528. doi: 10.47162/RJME.63.3.06.
We aimed to investigate immunohistochemical expression of the p53 tumor suppressor protein, and the B-cell lymphoma-2 (Bcl-2) apoptotic protein in colorectal adenocarcinoma patients with or without type 2 diabetes mellitus (T2DM). Tissue sections from 95 paraffin-embedded colorectal adenocarcinomas, originating from 52 T2DM and 43 non-diabetic patients, were immunostained for p53 [Ventana mouse monoclonal primary antibody (mAb) in vitro diagnostic (IVD) anti-p53, clone Bp53-11] and Bcl-2 (Ventana mAb IVD anti-Bcl-2, clone Bcl-2/124). Immunohistochemistry analysis did not find statistically significant differences between the two groups, but analysis on subgroups of patients in terms of presence or absence of obesity identified overexpression of p53 (>70% of cells) in the T2DM obese patients compared to non-diabetics. Overexpression of p53 was present in 80% of tumor cells coming from T2DM obese patients compared to 37.2% of tumor cells coming from non-diabetics obese and non-obese, and in 36.6% of tumor cells coming from non-diabetic non-obese patients (p=0.024). There was a single non-diabetic obese patient with p53 overexpression. Most cancer cells of T2DM obese patients presented more frequently p53 overexpression by comparison with cancer cells of the T2DM non-obese patients (80% vs 40.5%, p=0.028). Bcl-2/p53 co-expression was an infrequent event in T2DM patients' group. The results of this study suggest that patients with colorectal adenocarcinoma that associate T2DM and obesity exhibit higher p53 protein expression in malignant cells. In conclusion, our research highlights that obesity is a potential key factor in the relationship between T2DM and colorectal cancer.
我们旨在研究抑癌蛋白 p53 和 B 细胞淋巴瘤-2（Bcl-2）凋亡蛋白在合并 2 型糖尿病（T2DM）与不合并 2 型糖尿病的结直肠腺癌患者中的免疫组化表达。免疫组化染色采用 Ventana 鼠单克隆抗体（IVD 抗 p53，克隆 Bp53-11）和 Ventana 鼠单克隆抗体（IVD 抗 Bcl-2，克隆 Bcl-2/124）对 95 例结直肠腺癌石蜡包埋组织进行 p53 和 Bcl-2 检测，这些组织来源于 52 例 T2DM 患者和 43 例非糖尿病患者。免疫组化分析未发现两组之间存在统计学差异，但对肥胖患者亚组进行分析时发现，与非糖尿病患者相比，T2DM 肥胖患者的 p53 过度表达（>70%的细胞）。T2DM 肥胖患者肿瘤细胞中 p53 过度表达率为 80%，而非糖尿病肥胖和非肥胖患者肿瘤细胞中 p53 过度表达率为 37.2%，非糖尿病非肥胖患者肿瘤细胞中 p53 过度表达率为 36.6%（p=0.024）。在非糖尿病肥胖患者中，仅发现 1 例 p53 过度表达患者。与 T2DM 非肥胖患者相比，T2DM 肥胖患者的大多数肿瘤细胞中 p53 过度表达更为常见（80%比 40.5%，p=0.028）。T2DM 患者中 Bcl-2/p53 共表达是一种罕见事件。这项研究表明，患有结直肠腺癌的合并 2 型糖尿病和肥胖的患者其恶性细胞中 p53 蛋白表达更高。总之，我们的研究结果强调了肥胖是 2 型糖尿病与结直肠癌之间关系的一个潜在关键因素。
